A new class of compounds developed by two University of Kentucky researchers shows promise as a nontoxic treatment of some cancers previously treated with toxic chemotherapy, the researchers report today.
Radiation therapy after lumpectomy for early-stage breast cancer can be safely delivered in higher daily doses to greatly reduce treatment time. This conclusion of a new Fox Chase Cancer Center study is good news for women who might opt to have a mastectomy instead of a lumpectomy because of the time commitment needed for the usual six-week radiation course with the breast-sparing surgical option.
The Honourable Tony Clement, Canadian Health Minister, congratulated the new Chair and the rest of the Board of Directors of the new Canadian Partnership Against Cancer Corporation, as they held their second Board meeting.
Results of a world-first, large-scale study of faulty genes and breast cancer, with significant Australian contributions including research from the University of Melbourne will be released in Nature today.
A genetic mutation that raises the risk of breast cancer is found in up to 60 percent of U.S. women, making it the first truly common breast cancer susceptibility gene.
A new report released by the Australian Institute of Health and Welfare (AIHW), examines levels of death and disability from a variety of diseases, injuries and health risks to determine the total ‘burden of disease’ in Australia.
Follow-up of breast cancer patients after their initial treatment is becoming “devalued and deregulated”, according to new research published online in the cancer journal, Annals of Oncology.
Researchers at the Abramson Family Cancer Research Institute of the University of Pennsylvania and the Dana-Farber Cancer Institute describe in this week?s issue of Science a new candidate breast-cancer susceptibility gene. The Rap80 gene is required for the normal DNA-repair function of the well-known breast cancer gene BRCA1.
A team led by Dana-Farber Cancer Institute scientists has developed a more human-like mouse model of cancer they say will aid the search for cancer-causing genes and improve the predictive value of laboratory drug testing.
The most significant single predictor of aggressive prostate cancer is an elevated rate of increase in prostate specific antigen (PSA) levels, according to a new study.